It began in 2020 with a coordinated push to generate public backlash to lockdowns. The ultimate aim was restoring normalcy, ...

May 19 (Reuters) - U.S. drugmaker Pfizer (PFE.N), opens new tab said it would license an experimental cancer treatment from China's 3SBio Inc (1530.HK), opens new tab, paying $1.25 billion upfront ...

WASHINGTON — The release of COVID-19 vaccine results after the 2020 election may have not been a “coincidence” — and could have been part of an effort by senior Pfizer executives to ...

NEW YORK, May 20, 2025--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading ...

US drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc, paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones are met.

Pfizer PFE announced that it is in-licensing global development and commercialization rights, ex-China, to SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, from Chinese biotech, 3SBio.

(Reuters) -U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc, paying $1.25 billion upfront and up to another $4.8 billion if developmental ...

Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to ...

Pfizer Ltd has reported an 85% jump in net profit at ₹330.94 crore in the fourth quarter ended March 2025, boosted by a gain in exceptional item from completion of asset sale and transfer.

(Reuters) -U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc, paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones ...

(Reuters) -U.S. drugmaker Pfizer said on Monday it has signed a licensing agreement worth about $6 billion with Chinese biopharmaceutical company 3SBio Inc for the development, manufacturing and ...

(Reuters) -Pfizer has signed a licensing agreement worth up to $6 billion with Chinese pharmaceutical products developer 3SBio Inc for the development, manufacturing and commercialization of a drug ...